WO2007006939A3 - Emulsion immuno-adjuvante thermoreversible - Google Patents

Emulsion immuno-adjuvante thermoreversible Download PDF

Info

Publication number
WO2007006939A3
WO2007006939A3 PCT/FR2006/001635 FR2006001635W WO2007006939A3 WO 2007006939 A3 WO2007006939 A3 WO 2007006939A3 FR 2006001635 W FR2006001635 W FR 2006001635W WO 2007006939 A3 WO2007006939 A3 WO 2007006939A3
Authority
WO
WIPO (PCT)
Prior art keywords
oil
thermoreversible
adjuvant
immuno
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/001635
Other languages
English (en)
Other versions
WO2007006939A2 (fr
Inventor
Marie-Francoise Klucker
Francois Dalencon
Patricia Probeck-Quellec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Sanofi Vaccines US Inc
Original Assignee
Sanofi Pasteur SA
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/fr
Priority to EA200800271A priority Critical patent/EA012376B1/ru
Priority to PL06778810T priority patent/PL1904099T3/pl
Priority to DK06778810T priority patent/DK1904099T3/da
Priority to AP2007004280A priority patent/AP2361A/xx
Priority to JP2008519966A priority patent/JP5300475B2/ja
Priority to KR1020087002704A priority patent/KR101328638B1/ko
Priority to MX2007016412A priority patent/MX2007016412A/es
Priority to EP06778810A priority patent/EP1904099B1/fr
Priority to CN2006800248369A priority patent/CN101217977B/zh
Priority to NZ564173A priority patent/NZ564173A/en
Priority to BRPI0614053-0A priority patent/BRPI0614053A2/pt
Priority to CA2613732A priority patent/CA2613732C/fr
Application filed by Sanofi Pasteur SA, Sanofi Pasteur Inc filed Critical Sanofi Pasteur SA
Priority to DE602006005671T priority patent/DE602006005671D1/de
Priority to AU2006268466A priority patent/AU2006268466B2/en
Publication of WO2007006939A2 publication Critical patent/WO2007006939A2/fr
Publication of WO2007006939A3 publication Critical patent/WO2007006939A3/fr
Priority to IL187967A priority patent/IL187967A0/en
Priority to TNP2008000001A priority patent/TNSN08001A1/fr
Anticipated expiration legal-status Critical
Priority to NO20080585A priority patent/NO336369B1/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)

Abstract

L'invention a pour objet une émulsion adjuvante huile-dans-eau comprenant au moins : du squalène, un solvant aqueux, un tensioactif non ionique qui est un polyoxyéthylène alkyl ether, un tensioactif non ionique hydrophobe, thermoréversible, et dont 90 % de la population volumique des gouttes d'huile a une taille inférieure à 200 nm. L'invention a également pour objet un procédé de préparation d'une composition immunogène selon lequel on mélange au moins un antigène vaccinal avec une émulsion huile-dans-eau, caractérisé en ce qu'on obtient l’émulsion huile-dans-eau par un procédé d'inversion de phase par variation de la température.
PCT/FR2006/001635 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoreversible Ceased WO2007006939A2 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AU2006268466A AU2006268466B2 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
BRPI0614053-0A BRPI0614053A2 (pt) 2005-07-07 2006-07-07 emulsão adjuvante de óleo-em-água, uso da referida emulsão, processo para preparação de uma composição imunogênica compreendendo pelo menos um antìgeno de vacina e uma emulsão óleo-em-água, e composição imunogênica
DK06778810T DK1904099T3 (da) 2005-07-07 2006-07-07 Termoreversibel immunoadjuvansemulsion
AP2007004280A AP2361A (en) 2005-07-07 2006-07-07 Immunological adjuvant emulsion.
JP2008519966A JP5300475B2 (ja) 2005-07-07 2006-07-07 熱可逆性免疫アジュバントエマルション
KR1020087002704A KR101328638B1 (ko) 2005-07-07 2006-07-07 열가역적 면역-보강제 에멀젼
MX2007016412A MX2007016412A (es) 2005-07-07 2006-07-07 Emulsion adyuvante inmunologica.
EP06778810A EP1904099B1 (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoréversible
CN2006800248369A CN101217977B (zh) 2005-07-07 2006-07-07 热致可逆的免疫佐剂乳液
EA200800271A EA012376B1 (ru) 2005-07-07 2006-07-07 Иммуно-адъювантная эмульсия
CA2613732A CA2613732C (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoreversible
PL06778810T PL1904099T3 (pl) 2005-07-07 2006-07-07 Emulsja immunologiczna współdziałająca
NZ564173A NZ564173A (en) 2005-07-07 2006-07-07 Thermoreversible immunological adjuvant emulsion
DE602006005671T DE602006005671D1 (en) 2005-07-07 2006-07-07 Thermoreversible immunadjuvansemulsion
IL187967A IL187967A0 (en) 2005-07-07 2007-12-06 Thermoreversible immuno-adjuvant emulsion
TNP2008000001A TNSN08001A1 (fr) 2005-07-07 2008-01-04 Emulsion immuno-adjuvante thermoreversible
NO20080585A NO336369B1 (no) 2005-07-07 2008-01-31 Olje-i-vann adjuvansemulsjon, anvendelse og fremgangsmåte for fremstilling derav, samt immunogen sammensetning og fremgangsmåte for fremstillling derav.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (fr) 2005-07-07 2005-07-07 Composition vaccinale comprenant une emulsion thermoreversible
FR0507240 2005-07-07
FR0508310 2005-08-04
FR0508310 2005-08-04

Publications (2)

Publication Number Publication Date
WO2007006939A2 WO2007006939A2 (fr) 2007-01-18
WO2007006939A3 true WO2007006939A3 (fr) 2007-04-05

Family

ID=37637538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001635 Ceased WO2007006939A2 (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoreversible

Country Status (24)

Country Link
EP (2) EP1904099B1 (fr)
JP (1) JP5300475B2 (fr)
KR (1) KR101328638B1 (fr)
CN (1) CN101217977B (fr)
AR (1) AR054822A1 (fr)
AT (1) ATE424845T1 (fr)
AU (1) AU2006268466B2 (fr)
BR (1) BRPI0614053A2 (fr)
CA (1) CA2613732C (fr)
CY (2) CY1108994T1 (fr)
DE (1) DE602006005671D1 (fr)
DK (2) DK2080522T3 (fr)
EA (1) EA012376B1 (fr)
ES (2) ES2390104T3 (fr)
IL (1) IL187967A0 (fr)
MX (1) MX2007016412A (fr)
NO (1) NO336369B1 (fr)
NZ (1) NZ564173A (fr)
PL (2) PL1904099T3 (fr)
PT (2) PT1904099E (fr)
SG (1) SG163584A1 (fr)
SI (2) SI1904099T1 (fr)
TN (1) TNSN08001A1 (fr)
WO (1) WO2007006939A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007052055A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ594482A (en) * 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP2010530362A (ja) * 2007-05-31 2010-09-09 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 皮内ｈｐｖペプチドワクチン接種
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
WO2010096868A1 (fr) * 2009-02-25 2010-09-02 Stiefel Research Australia Pty Ltd Composition de mousse à usage topique
NZ599666A (en) 2009-10-09 2014-11-28 Cbio Ltd Chaperonin 10 variants
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
WO2012100302A1 (fr) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Vaccins associés
EP2578974A1 (fr) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Chaîne de traitement pour la production de particules lyophilisées
NZ714625A (en) 2012-03-23 2017-02-24 Pitney Pharmaceuticals Pty Ltd Kinase inhibitors for the treatment of cancer
HK1203358A1 (en) 2012-06-05 2015-10-30 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (fr) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Compositions immunogènes et procédés associés
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
EP3202397B1 (fr) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Composés pour le traitement de maladies associées à la voie mtor
CN103784953B (zh) * 2012-10-26 2018-04-10 上海医药工业研究院 作为疫苗佐剂的水包油型亚微乳及其制备方法
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931296B1 (fr) 2012-12-17 2019-02-27 NewSouth Innovations Pty Limited Traitement de maladies impliquant la mucine
EP3446708A1 (fr) 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccins pour le traitement du cancer et compositions pour améliorer l'efficacité de vaccins
EP3016968B1 (fr) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnostic et traitement de maladies autoimmunes
CN105288614A (zh) * 2014-06-18 2016-02-03 潘皓 一种疫苗组合物及其制备方法
EP3171954B1 (fr) 2014-07-21 2018-06-27 Sanofi Pasteur SA Dispositif d'alimentation de liquide permettant la génération de gouttelettes et son utilisation pour produire une composition vaccinale
CN116603058A (zh) 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2017137085A1 (fr) 2016-02-11 2017-08-17 Sanofi Pasteur Vaccins contre la méningite comprenant des subtilinases
BR112018069100A2 (pt) * 2016-03-23 2019-01-29 Intervet International B.V. uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
US12065482B2 (en) 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
WO2021231729A1 (fr) 2020-05-13 2021-11-18 Sanofi Nanoparticules d'hémagglutinine de souche stabilisée avec adjuvant et méthodes d'utilisation de celles-ci pour induction d'anticorps antigrippaux largement neutralisants
KR20230054719A (ko) 2020-08-24 2023-04-25 사노피 파스퇴르 인크 Sars-cov-2 감염에 대한 백신
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
CN118662475B (zh) * 2023-03-16 2026-02-06 清华大学 固体化自微乳疫苗的制备与应用
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
CN116531514A (zh) * 2023-05-29 2023-08-04 大连理工大学 一种烷基糖苷表面活性剂在铝佐剂冻干中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299884B1 (en) * 1989-05-25 2001-10-09 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US20030022852A1 (en) * 2000-03-10 2003-01-30 Nest Gary Van Biodegradable immunomodulatory formulations and methods for use thereof
US20030060559A1 (en) * 2001-03-21 2003-03-27 Madash, Llc Thermally reversible water in oil in water emulsions
US6544518B1 (en) * 1999-04-19 2003-04-08 Smithkline Beecham Biologicals S.A. Vaccines
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
EP0436537A4 (en) 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299884B1 (en) * 1989-05-25 2001-10-09 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6544518B1 (en) * 1999-04-19 2003-04-08 Smithkline Beecham Biologicals S.A. Vaccines
US20030022852A1 (en) * 2000-03-10 2003-01-30 Nest Gary Van Biodegradable immunomodulatory formulations and methods for use thereof
US20030060559A1 (en) * 2001-03-21 2003-03-27 Madash, Llc Thermally reversible water in oil in water emulsions

Also Published As

Publication number Publication date
PL2080522T3 (pl) 2012-11-30
PL1904099T3 (pl) 2009-08-31
IL187967A0 (en) 2008-03-20
ATE424845T1 (de) 2009-03-15
PT2080522E (pt) 2012-10-01
MX2007016412A (es) 2008-03-07
CA2613732A1 (fr) 2007-01-18
SI1904099T1 (sl) 2009-08-31
NO336369B1 (no) 2015-08-10
JP2009500382A (ja) 2009-01-08
KR101328638B1 (ko) 2013-11-27
EP2080522A1 (fr) 2009-07-22
ES2322102T3 (es) 2009-06-16
EP1904099B1 (fr) 2009-03-11
JP5300475B2 (ja) 2013-09-25
ES2390104T3 (es) 2012-11-06
CY1113414T1 (el) 2016-06-22
DK2080522T3 (da) 2012-10-08
DE602006005671D1 (en) 2009-04-23
CN101217977B (zh) 2013-03-06
AU2006268466A1 (en) 2007-01-18
CY1108994T1 (el) 2014-07-02
WO2007006939A2 (fr) 2007-01-18
NZ564173A (en) 2010-10-29
CN101217977A (zh) 2008-07-09
EP2080522B1 (fr) 2012-07-04
NO20080585L (no) 2008-03-26
BRPI0614053A2 (pt) 2011-03-09
AU2006268466B2 (en) 2011-11-10
TNSN08001A1 (fr) 2009-07-14
CA2613732C (fr) 2013-12-10
DK1904099T3 (da) 2009-06-08
EP1904099A2 (fr) 2008-04-02
SI2080522T1 (sl) 2012-10-30
AR054822A1 (es) 2007-07-18
EA200800271A1 (ru) 2008-04-28
EA012376B1 (ru) 2009-10-30
KR20080030076A (ko) 2008-04-03
SG163584A1 (en) 2010-08-30
PT1904099E (pt) 2009-05-29

Similar Documents

Publication Publication Date Title
SG163584A1 (en) Thermoreversible immuno-adjuvant emulsion
WO2007098186A3 (fr) Compositions d'adjuvant et de vaccin
CA2521051A1 (fr) Emulsions microfluidifiees d'huile dans l'eau et compositions de vaccins
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
EP2340710A3 (fr) Formulation stable sous la forme d'une emulsion, limitant l'interaction à l'interface eau-huile
JP2009500382A5 (fr)
TW200600108A (en) Microfluidized oil-in-water emulsions and vaccine compositions
EP2319484A3 (fr) Composition d'émulsion d'eau dans l'huile et son procédé de préparation
WO2008039564A8 (fr) Procédé de solubilisation d'huiles aromatisantes
HRP20080235T3 (hr) Formulacija vakcine koja sadrži emulziju ulje-u-vodi
WO2008104717A3 (fr) Procédé de préparation de nano-émulsions
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EA200801078A1 (ru) Микроэмульсии для применения в пищевых продуктах и напитках
WO2009121069A3 (fr) Compositions et procédés de préparation de nanoémulsions
WO2010092479A3 (fr) Vaccins contre la grippe comportant des quantités réduites de squalène
WO2001089474A3 (fr) Formulation
AR063704A1 (es) Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
WO2001060402A3 (fr) Vaccin antigrippal a base de proteosomes
CL2008001383A1 (es) Composición lactea o de sustituto lacteo aireada y liofilizada que comprende un ingrediente lacteo o substituto lacteo, un emulsificante, un mejorador de la viscosidad; y metodo para preparar dicha composicion.
AR053833A1 (es) Composicion inmunogenetica
RU2007106055A (ru) Эмульсия антиперспиранта или дезодоранта, содержащая неионогенный эмульгатор и коллоидный диоксид кремния
WO2009053601A3 (fr) Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant
MX2016001170A (es) Fluidos espaciadores emulsionados estables en aceite en agua.
EA201001478A1 (ru) Вакцина

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 187967

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 564173

Country of ref document: NZ

Ref document number: 2006778810

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/016412

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2613732

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006268466

Country of ref document: AU

Ref document number: 2008519966

Country of ref document: JP

Ref document number: 92/CHENP/2008

Country of ref document: IN

Ref document number: 200680024836.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087002704

Country of ref document: KR

Ref document number: 2006268466

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006268466

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200800271

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006778810

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0614053

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080107